当前位置：
X-MOL 学术
›
Bioorg. Med. Chem.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
A critical update on the strategies towards modulators targeting androgen receptors.
Bioorganic & Medicinal Chemistry ( IF 3.3 ) Pub Date : 2020-05-12 , DOI: 10.1016/j.bmc.2020.115554 Hongyu Luan 1 , Pengfei Xu 1 , Ying Meng 1 , Zhiyu Li 1 , Jinlei Bian 1
中文翻译：
关于靶向雄激素受体的调节剂策略的重要更新。
更新日期：2020-05-12
Bioorganic & Medicinal Chemistry ( IF 3.3 ) Pub Date : 2020-05-12 , DOI: 10.1016/j.bmc.2020.115554 Hongyu Luan 1 , Pengfei Xu 1 , Ying Meng 1 , Zhiyu Li 1 , Jinlei Bian 1
Affiliation
|
Prostate cancer is the most common carcinoma of the male urinary system in developed countries. Androgen deprivation therapy has been commonly used in the treatment of prostate cancer for decades, but most patients will inevitably develop into more aggressive castration-resistant prostate cancer. Therefore, novel strategies are urgent to address this resistance mechanism. In this review, we discussed some new strategies for targeting androgen receptors through degradation pathways as potential treatments for prostate cancer.
中文翻译：
关于靶向雄激素受体的调节剂策略的重要更新。
在发达国家，前列腺癌是男性泌尿系统最常见的癌症。雄激素剥夺疗法已被广泛用于前列腺癌的治疗数十年，但大多数患者不可避免地会发展为更具侵略性的去势抵抗性前列腺癌。因此，迫切需要新的策略来解决这种抵抗机制。在这篇综述中，我们讨论了通过降解途径靶向雄激素受体的一些新策略，作为前列腺癌的潜在治疗方法。
京公网安备 11010802027423号